Profile picture of Yasir Khan

Dr Yasir Khan

Profile picture of Yasir Khan

MBBS, FRACP

Medical Oncologist
Call
Enquire
Referrals

Dr Yasir Khan is a strong advocate for clinical trials and local research, ensuring his patients have access to the latest treatment options close to home. He brings a holistic, evidence-based approach to his practice and his patients benefit from his clinical research background and deep understanding of cancer care. His patient-centred approach emphasises clear communication and collaborative decision-making.

Biography

Dr Yasir Khan is a medical oncologist at Icon Cancer Centre Midland. In 2008 he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at the University of Health & Sciences in Lahore, Pakistan before relocating to Western Australia (WA). Dr Khan subsequently commenced specialist oncology training at Sir Charles Gairdner Hospital and Fiona Stanley Hospital in WA. In 2020, he completed a one-year clinical research fellowship in melanoma and kidney cancers at the Royal Marsden Hospital in London. During his fellowship, Dr Khan was the lead clinical research fellow in novel cell therapy clinical trials, collaborating with leading oncologists and researchers on multiple research projects.

Dr Khan has been Head of Oncology at Peel Health Campus since September 2021 and was appointed Head of Medical Specialities in August 2024. He also works at St. John of God (SJOG) Midland Hospital and is an adjunct clinical senior lecturer at Curtin University. He is actively involved in mentoring medical students and junior doctors.

Dr Khan maintains an active interest in clinical trials, medical education and research and has previous experience as a sub-investigator on various clinical trials including autologous tumour-infiltrating lymphocyte and NAR-T cell therapies. He has published several articles and abstracts in peer-reviewed journals and presented at state and national meetings.

Dr Khan is a fellow of the Royal Australasian College of Physicians (FRACP) and a member of several leading Australian and New Zealand cancer trial groups. He has expertise in immunotherapy treatments and novel immunotherapy agents. Dr Yasir Khan treats a broad range of malignancies and has a special interest in novel immunotherapy agents, thoracic cancers, breast cancer, genitourinary cancers, gastrointestinal cancers and melanoma.

Publications

  • Fendler A, Au L, Khan Y, Turajlic S et al. (2021). Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 1–17. https://doi.org/10.1038/s43018-021-00275-9

  • Khan, Y., Slattery, T. D., & Pickering, L. M. (2020). Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers, 12(12), 3750. https://doi.org/10.3390/cancers12123750

  • Meehan K, Leslie C, Khan Y, LIM AM et al. (2020). Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease. Cancer Medicine. https://doi.org/10.1002/cam4.3106

  • Pires da Silva I, Ahmed T, Khan Y, Larkin J, Menzies AM et al. (2022). Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 40(10), 1068–1080. https://doi.org/10.1200/jco.21.01701

  • Serra-Bellver P, Versluis JM, Khan Y, Long G, Larkin J, Lorigan P et al. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer, 176, 121–132. https://doi.org/10.1016/j.ejca.2022.09.004

Special Interests

Dr Yasir Khan accepts referrals for all cancer types, with a special clinical interest in:

  • Breast cancer
  • Gastrointestinal cancer
  • Genitourinary cancer
  • Melanoma
  • Thoracic cancer

Languages spoken

  • English

Icon Locations

Visiting Locations

St. John of God Midland Hospital

Affiliations & Memberships

  • American Society of Clinical Oncology (ASCO)
  • Australasian Lung Cancer Trials Group (ALTG)
  • Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
  • Australia New Zealand Gynaecological Oncology Group (ANZGOG)
  • Royal Australasian College of Physicians (RACP)
  • WA Clinical Oncology Group (WACOG)

Publications

  • Fendler A, Au L, Khan Y, Turajlic S et al. (2021). Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer, 1–17. https://doi.org/10.1038/s43018-021-00275-9

  • Khan, Y., Slattery, T. D., & Pickering, L. M. (2020). Individualizing Systemic Therapies in First Line Treatment and beyond for Advanced Renal Cell Carcinoma. Cancers, 12(12), 3750. https://doi.org/10.3390/cancers12123750

  • Meehan K, Leslie C, Khan Y, LIM AM et al. (2020). Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease. Cancer Medicine. https://doi.org/10.1002/cam4.3106

  • Pires da Silva I, Ahmed T, Khan Y, Larkin J, Menzies AM et al. (2022). Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 40(10), 1068–1080. https://doi.org/10.1200/jco.21.01701

  • Serra-Bellver P, Versluis JM, Khan Y, Long G, Larkin J, Lorigan P et al. (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer, 176, 121–132. https://doi.org/10.1016/j.ejca.2022.09.004

Search

Contact us
Become a patient